All Featured Insights

DOJ sues to block UHG-Amedisys deal, Cigna quashes Humana merger talks, and Johnson & Johnson sues to revive its 340B rebate program.

The latest Kaufman Hall Report includes an inside look at resetting organizational enterprise strategy.

Watch an engaging discussion with Moody’s, Fitch and S&P on their latest industry outlooks and hear top-of-mind topics including cyber preparedness, financial performance and capital spending as we head into the second half of the year, and contemporary strategies for long-term sustainability.

Hospitals and health systems that participate in the federal 340B Drug Pricing Program are currently facing challenges on multiple fronts, including manufacturer restrictions and program audits, legal challenges, and constantly-evolving federal and state requirements for participation.